In the ongoing quest to conquer Alzheimer's disease (AD), a recent Cochrane review has cast a shadow of doubt over the efficacy of amyloid-targeting monoclonal antibodies, specifically donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai). The review, published on April 16, 2026, analyzed 17 studies involving 20,342 participants, concluding that these drugs likely have little to no impact on functional ability or cognitive function in individuals with mild cognitive impairment or mild dementia. This finding has sparked a heated debate among experts, with some questioning the review's methodology and others emphasizing the importance of interpreting the results with nuance.
What makes this particularly fascinating is the review's focus on the removal of amyloid from the brain, a key target for AD treatments. The authors suggest that successful amyloid removal does not translate to clinically meaningful improvements in cognitive function or functional ability. This raises a deeper question: if the removal of amyloid is not the key to unlocking therapeutic success, what is? Personally, I think this highlights the complexity of AD and the need for a multifaceted approach to treatment.
One thing that immediately stands out is the review's finding that amyloid-targeting monoclonal antibodies may actually increase the risk of amyloid-related imaging abnormalities related to oedema (ARIA E). This is a critical detail that many people might overlook, as it suggests a potential downside to the very treatment being targeted. What this really suggests is that the search for effective AD treatments must consider not only the benefits but also the potential risks.
From my perspective, the Cochrane review's conclusion that further research should focus on other mechanisms of action is well-founded. However, I argue that this should not be seen as a setback for AD research. Instead, it should be viewed as an opportunity to explore a broader range of therapeutic targets and approaches. The pipeline of potential therapies is indeed more diverse and promising than ever before, and this review should serve as a catalyst for innovation rather than a barrier.
What many people don't realize is that the development of AD treatments has been a long and winding road. The search for effective therapies has been marked by both successes and setbacks, with many drugs failing to meet expectations. The Cochrane review's inclusion of failed drug trials in its analysis is a reminder of this history and the importance of learning from past mistakes. It is through this process of trial and error that we make progress.
If you take a step back and think about it, the Cochrane review's findings should be seen as a call to action rather than a cause for despair. They highlight the need for continued research and innovation in AD treatment, and they underscore the importance of a nuanced approach to interpreting scientific findings. As experts, we must continue to push the boundaries of what is possible, even in the face of setbacks. The future of AD treatment is bright, and it is up to us to ensure that it remains so.
